114 related articles for article (PubMed ID: 10803937)
1. Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy.
Schäfer H; Hübel K; Bohlen H; Mansmann G; Hegener K; Richarz B; Oberhäuser F; Wassmer G; Hölscher AH; Pichlmaier H; Diehl V; Engert A
Ann Hematol; 2000 Mar; 79(3):143-51. PubMed ID: 10803937
[TBL] [Abstract][Full Text] [Related]
2. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial.
Schaefer H; Engert A; Grass G; Mansmann G; Wassmer G; Hubel K; Loehlein D; Ulrich BC; Lippert H; Knoefel WT; Hoelscher AH
Ann Surg; 2004 Jul; 240(1):68-75. PubMed ID: 15213620
[TBL] [Abstract][Full Text] [Related]
3. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.
Weiss M; Voglic S; Harms-Schirra B; Lorenz I; Lasch B; Dumon K; Gross-Weege W; Schneider EM
Intensive Care Med; 2003 Jun; 29(6):904-914. PubMed ID: 12682721
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients.
Weiss M; Gross-Weege W; Schneider M; Neidhardt H; Liebert S; Mirow N; Wernet P
J Crit Care; 1995 Mar; 10(1):21-6. PubMed ID: 7538851
[TBL] [Abstract][Full Text] [Related]
5. Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.
Hübel K; Mansmann G; Schäfer H; Oberhäuser F; Diehl V; Engert A
Cytokine; 2000 Dec; 12(12):1797-800. PubMed ID: 11097751
[TBL] [Abstract][Full Text] [Related]
6. Effect of preoperative prophylaxis with filgrastim in cancer neck dissection.
Wenisch C; Werkgartner T; Sailer H; Patruta S; Krause R; Daxboeck F; Parschalk B
Eur J Clin Invest; 2000 May; 30(5):460-6. PubMed ID: 10809907
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
8. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery.
Schneider C; von Aulock S; Zedler S; Schinkel C; Hartung T; Faist E
Ann Surg; 2004 Jan; 239(1):75-81. PubMed ID: 14685103
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant human granulocyte-colony stimulating factor in colorectal surgery.
Wiik HT; Syrjälä HP; Silvennoinen-Kassinen SH; Laurila JJ; Haukipuro KA
Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):819-22. PubMed ID: 10614959
[TBL] [Abstract][Full Text] [Related]
11. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group.
Kuritzkes DR; Parenti D; Ward DJ; Rachlis A; Wong RJ; Mallon KP; Rich WJ; Jacobson MA
AIDS; 1998 Jan; 12(1):65-74. PubMed ID: 9456256
[TBL] [Abstract][Full Text] [Related]
12. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.
Halpern W; Riccobene TA; Agostini H; Baker K; Stolow D; Gu ML; Hirsch J; Mahoney A; Carrell J; Boyd E; Grzegorzewski KJ
Pharm Res; 2002 Nov; 19(11):1720-9. PubMed ID: 12458679
[TBL] [Abstract][Full Text] [Related]
13. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Ossenkoppele GJ; van der Holt B; Verhoef GE; Daenen SM; Verdonck LF; Sonneveld P; Wijermans PW; van der Lelie J; van Putten WL; Löwenberg B
Leukemia; 1999 Aug; 13(8):1207-13. PubMed ID: 10450748
[TBL] [Abstract][Full Text] [Related]
16. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
17. Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor.
Carulli G; Mattii L; Azzarà A; Brizzi S; Galimberti S; Zucca A; Benedetti E; Petrini M
Am J Hematol; 2006 May; 81(5):318-23. PubMed ID: 16628714
[TBL] [Abstract][Full Text] [Related]
18. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia.
deBoisblanc BP; Mason CM; Andresen J; Logan E; Bear MB; Johnson S; Shellito J; Summer WR; Nelson S
Respir Med; 1997 Aug; 91(7):387-94. PubMed ID: 9327037
[TBL] [Abstract][Full Text] [Related]
20. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.
Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G
Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
